RIGL · XBRL financial data

Rigel Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RIGL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	109	149	120	117	179	294
Cost of goods and services sold	1	1	2	7	19	20
Research and development	—	—	—	25	23	33
Selling, general and administrative	77	92	112	106	113	116
Operating income (loss)	(29)	(12)	(56)	(20)	24	125
Interest income	1	0	1	2	2	4
Interest expense	1	5	4	7	8	7
Income tax expense (benefit)	—	1	—	0	1	(245)
Net income (loss)	(30)	(18)	(59)	(25)	17	367
Earnings per share, basic‡ USD per share	(1.80)	(1.10)	(3.40)	(1.40)	0.99	20.40
Earnings per share, diluted‡ USD per share	(1.80)	(1.10)	(3.40)	(1.40)	0.99	19.48
Weighted average shares, basic‡ millions of shares	17	17	17	17	18	18
Weighted average shares, diluted‡ millions of shares	17	17	17	17	18	19

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal years (RIGL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	30	19	24	33	57	41
Short-term investments	27	106	34	24	21	114
Accounts receivable	16	15	40	31	42	52
Inventory	2	7	9	6	6	12
Prepaid and other current assets	14	7	8	6	10	22
Total current assets	89	154	116	99	135	240
Property and equipment, net	3	2	1	0	0	0
Right-of-use asset	18	10	2	1	0	1
Total assets	110	167	134	117	164	514
Accounts payable	4	4	23	7	3	7
Accrued liabilities	4	4	—	—	—	—
Total current liabilities	41	64	65	53	63	99
Lease liability, non-current	11	1	1	0	0	0
Total liabilities	—	137	148	146	161	122
Accumulated deficit	(1,306)	(1,324)	(1,382)	(1,408)	(1,390)	(1,023)
Total stockholders' equity	34	30	(14)	(29)	3	391
Total liabilities and equity	110	167	134	117	164	514
Common shares outstanding (cover page)‡ millions of shares	17	17	17	18	18	18

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal years (RIGL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(30)	(18)	(59)	(25)	17	367
Stock-based compensation	7	9	12	9	12	13
Depreciation and amortization	1	1	1	1	2	2
Net cash from operating activities	(52)	6	(74)	(6)	31	76
Purchases of property and equipment	1	1	0	—	—	—
Net cash from investing activities	47	(80)	73	(4)	4	(92)
Net cash from financing activities	13	63	7	18	(12)	1

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Rigel Pharmaceuticals	61	79	31*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Amarin	157	40	9.2*	not reported	—	Q3 FY26 10-QSep 30, 2026
Usana Health Sciences	169	223	23*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Altimmune	63	not reported	(24)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288	1	(25)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.